查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1908235

寡核苷酸CDMO市場規模、佔有率和趨勢分析報告：按服務、類型、應用、最終用途、地區和細分市場預測（2025-2033年）

Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Service, By Type, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

寡核苷酸CDMO市場概覽

2024年全球寡核苷酸CDMO市場規模估計為9.1178億美元，預計2033年將達到31.6897億美元。

預計從 2025 年到 2033 年，該市場將以 14.98% 的複合年成長率成長。推動市場成長的因素包括：反義和 siRNA 療法的臨床研發管線不斷增加、除疫苗外，基於 mRNA 的療法的應用日益廣泛，以及生物技術公司為降低生產複雜性而增加的外包。

此外，RNA療法和反義療法研發管線的不斷成長，也推動了對專業生產合作夥伴的需求，以幫助擴大生產規模。隨著這些候選藥物進入後期臨床試驗階段，申辦方面臨著產能限制和日益嚴格的純度要求，因此他們轉向經驗豐富的合約研發生產機構（CDMO），以實現可擴展且符合規範的生產。在多個研發階段對符合GMP標準的原料的需求，也推動了外包趨勢，從而促進了該領域契約製造服務的穩定成長。

此外，寡核苷酸化學日益複雜，需要先進的合成平台和分析能力，而許多新興生物技術公司無法自行開發這些平台和能力，這進一步推動了市場成長。偶聯寡核苷酸、先進遞送系統和更長序列等多項進展帶來了額外的技術挑戰，促使企業依賴擁有成熟技術的合約研發生產機構（CDMO）。因此，能夠提供高產率、低雜質含量和靈活批量放大生產的技術先進的供應商在整個研發過程中變得至關重要。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 寡核苷酸CDMO市場：變數、趨勢和範圍

  • 市場趨勢展望
  • 寡核苷酸CDMO市場的市場動態
  • 技術展望
  • 定價模式分析
  • 關稅影響分析
  • 供應鏈分析
  • 市場分析工具

第4章 寡核苷酸CDMO市場：依服務類型分類的估算與趨勢分析

  • 全球寡核苷酸CDMO市場服務變化分析
  • 全球寡核苷酸CDMO市場規模及趨勢分析（依服務類型分類，2021-2033年）
  • 契約製造
  • 合約開發

第5章 寡核苷酸CDMO市場按類型分類、估算和趨勢分析

  • 全球寡核苷酸CDMO市場類型變異分析
  • 全球寡核苷酸CDMO市場規模及趨勢分析（按類型分類）（2021-2033年）
  • 反義寡核苷酸
  • 小干擾RNA
  • 其他寡核苷酸

第6章：寡核苷酸CDMO市場：按應用分類的估算與趨勢分析

  • 全球寡核苷酸CDMO市場使用情形變化分析
  • 全球寡核苷酸CDMO市場規模及趨勢分析（依應用領域分類，2021-2033年）
  • 治療
  • 研究
  • 診斷

7. 寡核苷酸CDMO市場：最終用途、估算與趨勢分析

  • 全球寡核苷酸CDMO市場最終用途差異分析
  • 全球寡核苷酸CDMO市場規模及趨勢分析（依最終用途分類），2021-2033年
  • 製藥和生物製藥公司
  • 診斷公司
  • 其他

8. 寡核苷酸CDMO市場按服務、最終用途、地區分類的預測和趨勢分析

  • 區域市場概覽
  • 全球市場概覽（按地區分類）
  • 市場規模、預測與趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 阿曼
    • 卡達

第9章 競爭情勢

  • 公司分類
    • 市場領導
    • 新興企業
  • 寡核苷酸CDMO市佔率分析，2024年
  • 公司簡介
    • PolyPeptide Group
    • STA Pharmaceutical Co. Ltd.
    • Bachem
    • Creative Peptides
    • Aurigene Pharmaceutical Services Ltd.
    • Merck KGaA
    • EUROAPI
    • Curia Global, Inc.
    • CordenPharm
    • Sylentis, SA
Product Code: GVR-4-68040-832-9

Oligonucleotide CDMO Market Summary

The global oligonucleotide CDMO market size was estimated at USD 911.78 million in 2024 and is projected to reach USD 3,168.97 million by 2033, growing at a CAGR of 14.98% from 2025 to 2033. The market is driven by the rising clinical pipeline of antisense and siRNA therapies, growing adoption of mRNA-based therapeutics beyond vaccines, and increasing outsourcing by biotech firms to reduce manufacturing complexity.

In addition, the increasing number of pipeline of RNA-based and antisense therapeutics is driving the need for specialized manufacturing partners to help them scale production. As these candidates progress into late-stage clinical trials, sponsors encounter capacity constraints and heightened purity requirements, prompting a shift toward experienced contract development and manufacturing organizations (CDMOs) for scalable and compliant production. The need for consistent GMP-grade materials across multiple development phases further strengthens outsourcing trends and supports the steady uptake of contract manufacturing services in this domain.

Furthermore, the growing complexity of oligonucleotide chemistry, which requires sophisticated synthesis platforms and analytical capabilities that many emerging biotech firms cannot develop internally is also contributing to market growth. Several advancements such as conjugated oligos, advanced delivery systems, and long-chain sequences is adding additional technical challenges which is encouraging companies to depend on CDMOs with proven expertise. Thus, technologically advanced providers that can deliver high yield, reduced impurity profiles, and flexible batch scaling are becoming crucial across the development range.

Global Oligonucleotide CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oligonucleotide CDMO market report based on service, type, application, end use, and region:

  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Manufacturing
  • Contract Development
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Antisense Oligonucleotides
  • Small Interfering RNA
  • Other Oligonucleotides
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Therapeutic
  • Research
  • Diagnostic
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biopharmaceutical Companies
  • Diagnostic Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Norway
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Landscape Insights

Chapter 3. Oligonucleotide CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Oligonucleotide CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunities
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Supply Chain Analysis
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Oligonucleotide CDMO Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Oligonucleotide CDMO Market Service Movement Analysis
  • 4.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
  • 4.4. Contract Manufacturing
    • 4.4.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Contract Development
    • 4.5.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oligonucleotide CDMO Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Oligonucleotide CDMO Market Type Movement Analysis
  • 5.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Antisense Oligonucleotides
    • 5.4.1. Antisense Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Small Interfering RNA
    • 5.5.1. Small Interfering RNA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Other Oligonucleotides
    • 5.6.1. Other Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oligonucleotide CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Oligonucleotide CDMO Market Application Movement Analysis
  • 6.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Therapeutic
    • 6.4.1. Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Research
    • 6.5.1. Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Diagnostic
    • 6.6.1. Diagnostic Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Oligonucleotide CDMO Market End Use Movement Analysis
  • 7.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical and Biopharmaceutical Companies
    • 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Diagnostic Companies
    • 7.5.1. Diagnostic Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use

  • 8.1. Regional Market Dashboard
  • 8.2. Global Regional Market Snapshot
  • 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.6. Oman
      • 8.8.6.1. Key Country Dynamics
      • 8.8.6.2. Competitive Scenario
      • 8.8.6.3. Regulatory Framework
      • 8.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.7. Qatar
      • 8.8.7.1. Key Country Dynamics
      • 8.8.7.2. Competitive Scenario
      • 8.8.7.3. Regulatory Framework
      • 8.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Oligonucleotide CDMO Market Share Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. PolyPeptide Group
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product/Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. STA Pharmaceutical Co. Ltd.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product/Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Bachem
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product/Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Creative Peptides
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product/Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Aurigene Pharmaceutical Services Ltd.
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product/Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Merck KGaA
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product/Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. EUROAPI
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product/Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Curia Global, Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product/Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. CordenPharm
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product/Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Sylentis, S.A.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product/Service Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 4 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 5 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 6 North America Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 9 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 11 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 12 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 13 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 14 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 15 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 17 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 24 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 25 UK Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 26 UK Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 27 UK Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 28 UK Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 29 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 30 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 31 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 32 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 33 France Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 34 France Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 35 France Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 36 France Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 37 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 38 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 39 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 40 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 41 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 42 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 44 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 45 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 46 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 47 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 48 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 49 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 50 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 51 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 52 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 53 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 54 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 55 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 56 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 62 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 63 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 64 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 65 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 66 China Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 67 China Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 68 China Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 69 China Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 70 India Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 71 India Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 72 India Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 73 India Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 74 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 75 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 76 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 77 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 78 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 79 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 80 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 81 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 82 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 83 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 84 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 85 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 86 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 87 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 88 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 89 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 90 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 91 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 92 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 93 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 94 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 95 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 96 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 97 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 98 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 99 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 100 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 101 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 102 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 103 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 104 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 105 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 106 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 107 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 112 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 113 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 114 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 115 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 116 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 117 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 118 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 119 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 120 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 121 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 122 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 123 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 124 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 125 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 126 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 127 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Oligonucleotide CDMO Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Commodity Flow Analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD Model Sizing & Forecasting
  • Fig. 10 Bottom-up Approach
  • Fig. 11 Market Snapshot
  • Fig. 12 Segment Snapshot
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent Market Outlook, 2024 (USD Million)
  • Fig. 15 Ancillary Market Outlook, 2024 (USD Million)
  • Fig. 16 Oligonucleotide CDMO Market Dynamics
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 PESTEL by SWOT Analysis
  • Fig. 19 Oligonucleotide CDMO Market Service Outlook: Segment Dashboard
  • Fig. 20 Oligonucleotide CDMO Market, by Service Segment: Market Share, 2025 & 2033
  • Fig. 21 Contract Manufacturing Market Estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Oligonucleotide CDMO Market Type outlook: Segment dashboard
  • Fig. 24 Oligonucleotide CDMO Market, by Type Segment: Market Share, 2025 & 2033
  • Fig. 25 Antisense Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Small Interfering RNA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Other Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Oligonucleotide CDMO Market Application outlook: Segment dashboard
  • Fig. 29 Oligonucleotide CDMO Market, by Application Segment: Market Share, 2025 & 2033
  • Fig. 30 Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Diagnostic Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Oligonucleotide CDMO Market End Use Outlook: Segment Dashboard
  • Fig. 34 Oligonucleotide CDMO Market, by End Use Segment: Market Share, 2025 & 2033
  • Fig. 35 Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Diagnostic Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Regional marketplace: Key Takeaways
  • Fig. 39 North America Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Spain Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Norway Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 UAE Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Oman Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Market Participant Categorization
  • Fig. 95 Heat Map Analysis